Indegene recognized among Financial Times High-Growth Companies in Asia-Pacific 2025

18 Mar 2025 Evaluate

Indegene has been recognized among Financial Times (FT) High-Growth Companies in Asia-Pacific 2025. Recognized for the second year in a row, the ranking features companies across Asia-Pacific with the strongest revenue growth - particularly those that harness technology or adapt business models to keep expanding.

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products. Its client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies. 

Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.


Indegene Share Price

569.90 2.65 (0.47%)
28-Mar-2025 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...